or Try an Advanced Search...

    Technical Analysis for NRXP - NeuroRx, Inc.

    Grade Last Price % Change Price Change
    F 2.81 -8.17% -0.25
    NRXP closed down 8.17 percent on Tuesday, May 7, 2024, on 2.16 times normal volume.
    Earnings due: May 14
    *** please verify all earnings dates ***
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Flat
    Historical NRXP trend table...
    Date Alert Name Type % Chg
    Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
    Calm After Storm Range Contraction 0.00%
    Inside Day Range Contraction 0.00%
    Wide Bands Range Expansion 0.00%
    Oversold Stochastic Weakness 0.00%
    20 DMA Resistance Bearish -8.17%
    200 DMA Resistance Bearish -8.17%
    New Uptrend Bullish -8.17%
    Stochastic Buy Signal Bullish -8.17%
    Pocket Pivot Bullish Swing Setup -8.17%
    Older End-of-Day Signals for NRXP ...

       Recent Intraday Alerts

    Alert Time
    10 DMA Support about 16 hours ago
    60 Minute Opening Range Breakdown about 16 hours ago
    Possible Inside Day about 18 hours ago
    2x Volume Pace about 22 hours ago
    1.5x Volume Pace about 22 hours ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    NRXP Chart by TradingView
    Basic chart:

    Profile

    NeuroRx, Inc. operates as a clinical stage-small molecule pharmaceutical company which develops novel therapeutics for the treatment of central nervous system disorders. Its drug candidate includes Cyclurad, an oral therapeutic for the treatment of acute/elevated suicidal ideation/crisis in bipolar depression. The company was incorporated in 2015 and is headquartered in Wilmington, Delaware.
    Classification
    Sector: Industrials
    Industry: Conglomerates
    Keywords: Life Sciences Health Sciences Health Care Central Nervous System Disorders Antidepressants Bipolar Disorder Treatment Of Central Nervous System Disorders Atypical Antipsychotics Bipolar Depression

    Is NRXP a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 3 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 7 NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) to Report First Quarter 2024 Financial Results on May 14, 2024
    May 6 NRx Pharmaceuticals climbs on positive results from its bipolar depression treatment trial
    May 6 NRx Pharmaceuticals (Nasdaq:NRXP) Announces Final Clinical Trial Results: Superior Safety Combined with Similar Efficacy in the Trial of NRX-101 Compared to Lurasidone in Suicidal Bipolar Depression
    Apr 30 Why Is NRx Pharmaceuticals Stock Falling After Data From Suicidal Bipolar Depression Study
    Apr 30 NRx Pharmaceuticals (Nasdaq:NRXP) Announces Promising Findings in Phase 2b/3 Clinical Trial of NRX-101 vs. Lurasidone for Treatment of Suicidal Bipolar Depression
    Apr 18 NRx Pharmaceuticals receives Nasdaq notice on demonstrating compliance with bid price requirement
    Apr 18 NRx Pharmaceuticals (NASDAQ:NRXP) Receives Notice from Nasdaq that the Company has Demonstrated Compliance with the Bid Price Requirement
    Apr 18 NRx Pharmaceuticals, Inc. Announces Pricing of $2.0 Million Underwritten Public Offering of Common Stock
    Apr 17 NRx Pharmaceuticals announces proposed underwritten public offering of common stock
    Apr 17 NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces New Data on NRX-101 Demonstrating No Damage to Intestinal and Vaginal Flora in Validated Rodent Models Compared to Standard Antibiotics: Potential Implications for Avoidance of C. Difficile infections
    See more NRXP news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 12.0
    52 Week Low 1.9
    Average Volume 493,408
    200-Day Moving Average 3.72
    50-Day Moving Average 4.44
    20-Day Moving Average 3.49
    10-Day Moving Average 2.81
    Average True Range 0.62
    RSI (14) 39.02
    ADX 27.01
    +DI 29.36
    -DI 27.84
    Chandelier Exit (Long, 3 ATRs) 4.13
    Chandelier Exit (Short, 3 ATRs) 3.77
    Upper Bollinger Bands 5.60
    Lower Bollinger Band 1.38
    Percent B (%b) 0.34
    BandWidth 120.97
    MACD Line -0.60
    MACD Signal Line -0.56
    MACD Histogram -0.0383
    Fundamentals Value
    Market Cap 239.32 Million
    Num Shares 85.2 Million
    EPS -0.50
    Price-to-Earnings (P/E) Ratio -5.62
    Price-to-Sales 0.00
    Price-to-Book 6.95
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 3.55
    Resistance 3 (R3) 3.60 3.42 3.42
    Resistance 2 (R2) 3.42 3.23 3.39 3.38
    Resistance 1 (R1) 3.11 3.11 3.02 3.06 3.34
    Pivot Point 2.93 2.93 2.88 2.90 2.93
    Support 1 (S1) 2.62 2.74 2.53 2.57 2.28
    Support 2 (S2) 2.44 2.62 2.41 2.24
    Support 3 (S3) 2.13 2.44 2.20
    Support 4 (S4) 2.08